Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung

University of North Carolina (UNC)

Status and phase: Completed; Phase 1

Conditions: Mucociliary Clearance

Treatments: Drug: Placebo; Drug: Mucinex 1200mg

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00902707

2009-MUC-01

Details and patient eligibility

About

The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body.

Enrollment: 12 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy
• Non smoker
• BMI 19-29
• Normal lung function

Exclusion criteria

• Pregnant
• Smokers
• Any illness

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

12 participants in 2 patient groups, including a placebo group

Mucinex 1200mg

Experimental group

Description:

Pill

Treatment:

Drug: Mucinex 1200mg

Placebo

Placebo Comparator group

Description:

Pill

Treatment:

Drug: Placebo